Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    EMA Accepts MAA For Dong-A ST's Ustekinumab Biosimilar

    On July 14, Dong-A ST announced that the European Medicines Agency accepted its Marketing Authorization Application for DMB-3115, a biosimilar referencing STELARA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    EMA Accepts Marketing Authorization Application For Alvotech's AVT05 (Golimumab)

    On November 4, 2024, Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
Article

EMA Adopts Positive Opinion For Amgen's Eculizumab Biosimilar Candidate BEKEMV®

On February 23, 2023, the European Medicines Agency (EMA) adopted a positive opinion for BEKEMV®.
United StatesFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP
  • Podcast

    Episode 367 - In-Conversation: Jamie Metzl On The Superconvergence Of The AI, Biotech & Genetics Revolutions (Podcast)

    Technology and health care futurist Jamie Metzl joins Howard Schweitzer, chief executive officer of Cozen O'Connor Public Strategies, for a wide-ranging conversation on the amazing technological revolutions...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Cozen O'Connor
    Cozen O'Connor
  • Article

    Eric Fader To Present Webinar, "Navigating Legal Issues In Neuromonitoring"

    On March 15, Eric Fader will be presenting a live webinar, "Navigating Legal Issues in Neuromonitoring," for The American Society of Neurophysiological Monitoring (ASNM). Founded in 1990, ASNM serves the field of intraoperative neurophysiologic monitoring
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    Eric Fader to Present Webinar, "Navigating Legal Issues in Neuromonitoring"

    On March 15, Eric Fader will be presenting a live webinar, "Navigating Legal Issues in Neuromonitoring," for The American Society of Neurophysiological Monitoring (ASNM).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Day Pitney LLP
    Day Pitney LLP
  • Article

    European Commission Approves Samsung Bioepis And Biogen's Aflibercept Biosimilar

    On November 18, 2024, Samsung Bioepis announced that the European Commission (EC) has approved its aflibercept biosimilar, OPUVIZ.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Exploring The Amgen Genus Claims Headed To High Court

    Head of Life Sciences Irena Royzman and associate Jeffrey Coleman authored a Law360 article titled "Exploring The Amgen Genus Claims Headed To High Court" on Jan. 10, 2023.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Herbert Smith Freehills Kramer LLP
    Herbert Smith Freehills Kramer LLP
  • Article

    FDA Accepts For Review Fresenius Kabi's BLA For Tocilizumab Biosimilar

    On August 1, 2022, Fresenius Kabi announced that the FDA accepted for review its Biologics License Application (BLA) for MSB11456, a biosimilar candidate for ACTEMRA (tocilizumab).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Accepts Sanofi And Regeneron's Dupixent SBLA For Priority Review

    On November 11, 2025, Sanofi and Regeneron announced that the FDA accepted for priority review its supplemental biologics license application ("sBLA") for Dupixent (dupilumab)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA And Tech Firms Address Regulatory Challenges Posed By Mobile Medical Devices

    Silicon Valley technology firms are increasingly confronting the challenges of clearing U.S. regulatory approval processes.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Fee Rates For Using Tropical Disease Priority Review Voucher In FY2015

    In the August 27, 2014, Federal Register, FDA announced the fee rate for tropical disease priority review vouchers, in addition to the normal PDUFA fee, will be $2,562,000.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Meetings And Opportunities For Comments On Patient-Focused Drug Development For Idiopathic Pulmonary Fibrosis And Heritable Bleeding Disorders

    The meetings are intended to allow FDA to collect patient perspectives on the impact of and treatment approaches for these disorders.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces New Director For CFSAN

    She will take over the CFSAN position from Landa, who has led the Center since 2010.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Public Hearing On Confidentiality Of Interim Results In Cardiovascular Outcome Safety Trials

    FDA requested comments and announced a public hearing on the confidentiality of interim results for certain cardiovascular outcomes trials.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Public Workshop On Antibacterial Drug Development

    In the May 31, 2016, Federal Register, FDA announced an upcoming public workshop regarding antibacterial drug development for patients with unmet need and developing antibacterial drugs that target a single species.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Announces Support For Study Data Tabulation Model Implementation Guide Version 3.2

    FDA is encouraging sponsors to use this guide in investigational study data provided in regulatory submissions to CBER and CDER.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    FDA Approves EYLEA® (Aflibercept) For Treatment Of Retinopathy Of Prematurity

    On February 8, 2023, Regeneron announced that the FDA approved its EYLEA® (aflibercept) injection for the treatment of retinopathy of prematurity (ROP) in preterm infants
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Approves LOQTORZI In All Lines Of Treatment For Recurrent Or Metastatic Nasopharyngeal Carcinoma

    On October 27, Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. Food and Drug Administration approved LOQTORZI (toripalimab-tpzi)...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    FDA Calls For Nonvoting Industry Representatives To Serve On CBERs Cellular, Tissue, And Gene Therapies Advisory Committee

    The chosen representative would represent industry interests on the committee.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Showing 101–120 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics